Overexpression and Characterization of the Human Mitochondrial and Cytosolic Branched-chain Aminotransferases*

Jamshid DavoodiDagger , Penny M. DrownDagger , Randy K. Bledsoe§, Reidar Wallin, Gregory D. Reinhartpar , and Susan M. HutsonDagger **

From the Departments of Dagger  Biochemistry and  Internal Medicine, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, § Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709, and the par  Department of Biochemistry and Biophysics, Texas A & M University, College Station, Texas 77843-2128

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
Conclusions
References

We have developed overexpression systems for the human branched-chain aminotransferase isoenzymes. The enzymes function as dimers and have substrate specificity comparable with the rat enzymes. The human cytosolic enzyme appears to turn over 2-5 times faster than the mitochondrial enzyme, and there may be anion and cation effects on the kinetics of both enzymes. The two proteins demonstrate similar absorption profiles, and the far UV circular dichroism spectra show that no global structural changes occur when the proteins are converted from the pyridoxal to pyridoxamine form. On the other hand, the near UV circular dichroism spectra suggest differences in the local environment surrounding tyrosines within these proteins. Both enzymes require a reducing environment for maximal activity, but the mitochondrial enzyme can be inhibited by nickel ions in the presence of reducing agents, while the cytosolic enzyme is unaffected. Chemical denaturation profiles of the proteins show that there are differences in structural stability. Titration of -SH groups with 5,5'-dithiobis(2-nitrobenzoic acid) suggests that no disulfide bonds are present in the mitochondrial enzyme and that at least two disulfide bonds are present in the cytosolic enzyme. Two -SH groups are titrated in the native form of the mitochondrial enzyme, leading to complete inhibition of activity, while only one -SH group is titrated in the cytosolic enzyme with no effect on activity. Although these proteins share 58% identity in primary amino acid sequence, the local environment surrounding the active site appears unique for each isoenzyme.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
Conclusions
References

Branched-chain aminotransferases (BCAT)1 catalyze reversible transamination of the short chain aliphatic branched-chain amino acids, leucine, isoleucine, and valine, to their respective alpha -keto acids. Although transamination of branched-chain amino acids in animals and microorganisms was observed in the 1950s (for a review, see Ref. 1), it was not until 1966 that Ichihara and Koyama (2) and Taylor and Jenkins (3) each reported independently that these reactions were catalyzed by a single enzyme.
<UP><SC>l</SC>-Leucine</UP>+&agr;-<UP>ketoglutarate ⇄ &agr;-Ketoisocaproate</UP>+<UP><SC>l</SC>-glutamate</UP>
<UP><SC>l</SC>-Valine</UP>+&agr;-<UP>ketoglutarate ⇄ &agr;-Ketoisovalerate</UP>+<UP><SC>l</SC>-glutamate</UP>
<UP><SC>l</SC>-Isoleucine</UP>+&agr;-<UP>ketoglutarate ⇄ &agr;-Keto-&bgr;-methylvalerate</UP>+<UP><SC>l</SC>-glutamate</UP>
<UP><SC>Reactions</SC> 1–3</UP>
Bacteria generally contain a single BCAT (4-6), but in mammals it has been established that there are two BCAT isoenzymes, a mitochondrial (BCATm) and a cytosolic (BCATc) form (7). In humans and rodents, BCATm is found in most tissues (1, 8). In contrast, BCATc is found almost exclusively in the brain (1, 9). Each rat isoenzyme has been purified (9, 10), and the cDNA sequences of the rat (11, 12) as well as the human (12, 13) BCATc and BCATm are now available. Recently, it has been reported that the mammalian BCATc gene may be regulated by the c-myc oncogene product (14) and that the BCAT may be a target for the anticonvulsant drug and nonmetabolizable leucine analog, gabapentin (15). Furthermore, in yeast, deletion of both BCAT genes results in severe growth retardation even after supplementation with branched-chain amino acids, suggesting that these enzymes perform an essential function in the cell (16). Nevertheless, the functional significance and structure of the individual eukaryotic BCAT isoenzymes is not yet known.

Another feature of the BCAT is their evolutionary relationship to the bacterial enzyme D-amino acid aminotransferase (17). Based on primary sequence comparisons, the BCAT and D-amino acid aminotransferase, which have opposite stereospecificity (L- versus D-amino acids), and another bacterial enzyme, 4-amino-4-deoxychorismate lyase, were placed in a separate folding class (fold type IV) (11, 12, 18). With a few exceptions, other known aminotransferases fall within the fold type I or L-aspartate aminotransferase superfamily. A unique feature of the fold type IV PLP-dependent enzymes is that the proton is added to or abstracted from the C4' atom of the coenzyme-imine or external aldimine intermediate on the re face instead of the si face of the PLP cofactor (19). The crystal structure of the PMP form of D-amino acid aminotransferase has been solved by Sugio et al. (20), and the structure of the Escherichia coli BCAT in the pyridoxal form has just been reported by Okada et al. (21). The folding pattern of both enzymes is not only different from that of other known PLP-dependent enzymes but also from that of other known proteins (20). The E. coli BCAT enzyme consists of six identical 34-kDa subunits that are an assembly of three dimer units around a three-fold axis (21, 22). On the other hand, the mammalian BCAT do not appear to be hexamers and have subunit molecular masses ranging from 41 to 46 kDa (11, 12). Thus, cloning and overexpression of both human BCAT isoenzymes has provided the tools necessary to develop a molecular model of the mammalian BCAT that may impact on our current understanding of this unusual class of PLP-dependent enzymes.

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
Conclusions
References

Plasmids, Bacterial Strains, Enzymes, and Chemicals-- Plasmids pT7Blue(R) and pET-28a were purchased from Novagen (Madison, WI). The pTrcHis vector was obtained from Invitrogen (Carlsbad, CA). Bacterial strains used were E. coli BL21DE3 and DH5-alpha . Restriction endonucleases and other DNA modification enzymes were purchased from Promega, Inc. Nucleotide sequencing was performed using the Sequenase version 2.0 7-deaza-dGTP sequencing kit (U.S. Biochemical Corp.).

Construction and Expression of phBCATm, phBCATc, and phBCATc2-- For human BCATm, the sense primer 5'-AGCCATATGGCCTCCTCCAGTTTCAAG-3' contained an NdeI restriction site. The last 18 nucleotides of the sense primer corresponded to the first 18 bases encoding the mature BCATm protein (12). The antisense primer 5'-GAGTGTCGCAACCACAT-3' corresponded to nucleotides 1316-1332 of the full-length human cDNA (12). For increased accuracy, a polymerase mixture of Taq and Pwo polymerases (Boehringer Mannheim) was used. The amplified product was cloned into the pT7 vector. The insert was sequenced on both strands, and the fidelity was verified by comparison with the original human BCATm cDNA clone. The purified cDNA was ligated into the pET-28a vector cut with NdeI. Following transformation, plasmid DNA isolated from single colonies was screened for correct orientation of the cDNA insert, and then the construct was used to transform BL21DE3 cells. Cells were grown to an A600 between 0.6 and 0.9, and expression was induced with 1 mM isopropyl-beta -D-thiogalactopyranoside. After 8 h, expression was approximately 8 mg of BCATm/liter of culture with a typical recovery of 6 mg of purified protein/liter of E. coli.

A similar strategy was used to construct the phBCATc expression vector. Using the cDNA sequence in Ref. 13 (accession number U21551), a sense primer was designed that contained an NheI site immediately preceding the codon for the initiator methionine followed by the nucleotides encoding the first 5 amino acids of the protein, 5'-TATGGCTAGCATGGATTGCAGTAACGGA-3'. The antisense primer 5'-TCAGGATAGCACAATTGTC-3' corresponded to nucleotides 1137-1155. Human brain cDNA was used in the polymerase chain reaction, and the amplified product was cloned into the pT7 vector and sequenced. The purified cDNA was ligated into the pTrcHis vector cut with NheI and HindIII. The phBCATc2 plasmid was engineered by ligating the full-length BCATc sequence into the pET-28a vector cut with SalI and NheI. BL21DE3 cells were grown and induced as described for phBCATm, and after 5-7 h, expression was 2 and 8 mg of BCATc/liter with phBCATc and phBCATc2, respectively. Typically, 50% of the expressed protein was recovered after purification.

Protein Purification-- Nickel-NTA resin (Qiagen, Chatsworth, CA) was used according to the manufacturer's instructions to purify the histidine-tagged recombinant proteins. For BCATm, cells harvested from 2 liters of culture were resuspended in extraction buffer containing 0.1 M sodium phosphate, pH 8.0, 0.01 M Tris-HCl, and 5 mM beta -mercaptoethanol. The mixture was sonicated for 10 1-min intervals at 70% duty cycle using a Branson model 250 sonifier. The extract was centrifuged for 8 min at 7800 × g at 4 °C. The supernatant was saved, and the pellet was resuspended in extraction buffer containing 4 M urea and sonicated as before. After centrifugation, the second supernatant was combined with the first supernatant to which urea had been added to 4 M. The total extract was incubated with 7 ml of 50% nickel-NTA resin equilibrated in the extraction buffer containing urea for 1 h at 4 °C with gentle stirring. The mixture was loaded into a column, and the resin was washed with the extraction buffer containing urea. The column was then washed with buffer A containing 0.01 M Tris, pH 7.5 (HCl), 20% glycerol, 150 mM NaCl, 5 mM beta -mercaptoethanol followed by buffer B, which contained 0.1 M sodium phosphate (pH 6.0), 0.01 M Tris-HCl, 750 mM NaCl, 10% glycerol. The column was washed further with buffer B containing 50 mM imidazole. The protein was eluted with buffer B containing 350 mM imidazole. The histidine tag was removed by digestion with thrombin (100 NIH units) in 50 mM Tris (pH 7.5), 150 mM NaCl for 1 h at 25 °C. The final purification step was hydrophobic interaction chromatography as described in Ref. 10 with the following modifications. The BCATm-containing fraction from the nickel-NTA column was incubated with 5 mM alpha -ketoisocaproate in 100 mM potassium phosphate at pH 7.5 on ice for 5 min before loading onto the column, and the elution gradient began at 35% saturated ammonium sulfate. The concentration of BCATm was determined from the absorbance at 280 nm using the extinction coefficient of 67,600 M-1 cm-1 per monomer.

For human BCATc in either the pTrcHis or pET-28a vector, extraction and nickel-NTA purification steps were identical to BCATm, except that urea was not added to any buffers. Following nickel-NTA chromatography, purification was carried out using hydroxyapatite chromatography. The BCATc containing fraction from the nickel-NTA column was loaded onto the hydroxyapatite column in 10 mM potassium phosphate, pH 7.0. Human BCATc was eluted with 200 mM potassium phosphate, pH 7.0. The final purification step was ion exchange chromatography using a Mono-Q column (Pharmacia Biotech Inc.) as described in Ref. 10 except that the buffer was 10 mM potassium phosphate, pH 8.0. The histidine tag remained on the recombinant protein when expressed from the pTrcHis vector, but when the pET-28a construct was used, the added histidines were cleaved with thrombin as described for BCATm. The concentration of BCATc with and without the histidine tag was determined from the absorbance at 280 nm using the extinction coefficients of 80,000 M-1 cm-1 and 86,300 M-1 cm-1 per monomer, respectively.

Storage Conditions-- Human BCATm was extremely sensitive to oxidation and required the presence of 100 mM DTT to remain fully active. If samples were purged with argon every other day, the enzyme retained significant activity for periods of up to 2 weeks at 4 °C. When stored in 50% glycerol at -20 °C with argon purging, BCATm was stable for as long as 4 months. BCATc was not as sensitive to oxidation and could be stored in the presence of 10 mM DTT without argon purging. BCATc was stable for about 2 weeks at 4 °C and for 3-4 months at -20 °C in 50% glycerol.

Amino Acid Analysis-- The extinction coefficient for each isoenzyme was calculated from the amino acid composition of each protein. The N terminus of each recombinant protein was verified by amino acid sequence analysis. Both composition analysis and N-terminal sequencing were performed by the Protein Analysis Core Laboratory of the Comprehensive Cancer Center of Wake Forest University.

Spectrophotometric Measurements-- Absorption spectra were taken with a Beckman DU 640 spectrophotometer. CD measurements were carried out with a JASCO J-720 spectropolarimeter equipped with a variable temperature accessory. The enzymes were converted to the PLP and PMP forms by incubation with the appropriate substrate followed by dialysis. The instrument was calibrated with ammonium-D-camphorsulfonate. CD spectra in the near UV region were measured in a 1-cm quartz cylindrical cuvette at a protein concentration of 1 mg/ml. In the far UV region, CD spectra were acquired using a protein concentration of 0.5 mg/ml in 5 mM potassium phosphate buffer and a 0.05-cm path length. The final spectra were the average of four accumulations. The CD spectra of the PLP and PMP forms of BCATm and BCATc were analyzed using the convex constraint algorithm described in Refs. 23 and 24. In all cases, the targeted protein CD spectrum was added to the appropriate data set, which contained 30 proteins, and the enlarged spectral set (30 + 1) was analyzed by CDANAL software (Jasco). Based on the quality of the fit, the number of pure components was set either at three or four, and the contribution of each element was obtained from the conformational weight matrix. Sigma values varied from 0.8 to 1.5.

Sulfhydryl Group Titrations-- 5-15 nmol of protein were dissolved in 1 ml of buffer containing 50 mM Tris-HCl (pH 7), 1 mM EDTA, and 6 M guanidine hydrochloride. The reaction was initiated by the addition of 200 µl of 10 mM DTNB at room temperature, and the absorbance at 412 nm was monitored for 15 min. The amount of free thiol was calculated from the liberated 2-nitro-5-thiobenzoate anion using a molar extinction coefficient of 14,150 (25). The same procedure was repeated in the absence of denaturant to determine the number of cysteines accessible to solvent. Cysteine titrations were also performed in the presence of either 10 mM alpha -ketoisocaproate or isoleucine.

Branched-chain Aminotransferase Assay and Steady State Kinetics-- Branched-chain aminotransferase activity was measured at 37 °C in 25 mM potassium phosphate buffer, pH 7.8, using 1 mM alpha -keto[1-14C]isovalerate and 12 mM isoleucine as described (9, 10). A unit of enzyme activity was defined as 1 µmol of valine formed per min at 37 °C. In the kinetic studies, bovine serum albumin was omitted, and the assay contained 2 mM DTT and 12.5 mM EDTA.

Reaction rates with the branched-chain amino acid/alpha -ketoglutarate pairs were determined from the formation of glutamate, which was assayed fluorimetrically by a slight modification of the method described by Williamson and Corkey (26). Briefly, excess alpha -ketoglutarate was removed from the neutralized sample by the addition of either 10 mM (BCATm) or 15 mM (BCATc) H2O2. Samples were incubated at room temperature for 5-15 min before an aliquot (250 µl) was added to 1 ml of assay buffer. NADH fluorescence was determined with an excitation wavelength of 340 nm using a FOCI Mark I spectrofluorimeter (Farrand Optical Co., New York). The kinetic parameters of the amino acid reactions were determined by holding the concentration of alpha -ketoglutarate constant at 5 mM for BCATm and 10 mM for BCATc. For the alpha -keto acid/glutamate pairs, reaction rates were determined from the formation of 1-14C-labeled branched-chain amino acid as described previously (7, 10). The glutamate concentration was kept constant at 100 mM as the high salt concentration affected the kinetic parameters. The data were fit to the following velocity equation.
v=(V<SUB><UP>max</UP></SUB>[<UP>S</UP>])/(K<SUB>m</SUB>+[<UP>S</UP>]) (Eq. 1)

The Km of alpha -ketoglutarate or glutamate was first estimated by varying the concentration of each branched-chain amino or alpha -keto acid at approximately 5 times Km. For each substrate pair, data were collected from six or seven concentrations of amino acid or alpha -keto acid. Kinetic parameters are the means and standard errors of 3-5 separate determinations from two different BCATm and BCATc preparations. In separate experiments, the apparent Km for alpha -ketoglutarate and glutamate was determined by varying the concentrations of both the amino acid and alpha -keto acid substrates simultaneously. The data were fit to the initial velocity rate equation pertaining to a ping-pong kinetic mechanism (27) via nonlinear regression in the approach outlined by Cleland (28).
v=(V<SUB><UP>max</UP></SUB>[<UP>A</UP>][<UP>B</UP>])/(K<SUB><UP>b</UP></SUB>[<UP>A</UP>]+K<SUB><UP>a</UP></SUB>[<UP>B</UP>]+[<UP>A</UP>][<UP>B</UP>]) (Eq. 2)

In this equation, the parameters Ka and Kb represent the Michaelis constants for substrates A (amino acid) and B (alpha -ketoacid), respectively.

Analytical Ultracentrifugation-- The equilibrium sedimentation experiments were performed in the Analytical Ultracentrifugation Facility at Wake Forest University. Using a Beckman Optima XL-A analytical ultracentrifuge, BCATm and BCATc in 25 mM Tris (pH 7.5), 150 mM KCl were centrifuged at 7500, 9000, 11,000, 14,000, and 40,000 rpm. Data were gathered after 12 and 14 h at each speed. The data were examined to verify that equilibrium was established. Partial specific volumes were calculated based on the amino acid composition of each protein as described by Laue et al. (29). Data analysis was performed using Origin software provided by Beckman.

Miscellaneous Procedures-- SDS-PAGE was carried out according to Laemmli (30) in 10% gels as described in Wallin et al. (10).

    RESULTS AND DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
Conclusions
References

Expression and Purification-- The human BCATm and BCATc have been cloned (12, 13). Mature BCATm consists of 365 amino acids with a calculated molecular mass of 41,300 daltons, while BCATc consists of 385 amino acids with a calculated molecular mass of 42,800 daltons. A comparison of the primary sequences of these proteins reveals that they are 58% identical to each other (see Fig. 1) and 74% (BCATc) and 82% (BCATm) identical to their respective rat enzymes. Identity is found throughout the overlapping primary sequences including the C terminus. The most significant differences in primary sequences are found in the N-terminal portion (BCATc, residues 1-50) of the proteins.


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 1.   Sequence alignment of recombinant human BCATc and BCATm after cleavage of the histidine tag by thrombin. Deduced amino acid sequences were aligned using the GAP analysis software (Genetics Computing Group Sequence Analysis Software Package, version 8.0) (34). Additional residues unique to the recombinant proteins are shown in lowercase italic type. The extra N-terminal residues for histidine-tagged BCATc are mggshhhhhhgmas. The active site lysine is boxed, and cysteine residues are shaded.

In initial attempts to overexpress BCATm in a variety of expression plasmids, low expression, inactive, or insoluble protein was observed. The BCATm cDNA was then cloned into the pET-28a vector, which introduced a six-histidine residue tag onto the N terminus of the protein. High levels of expression of active protein were obtained, but the majority of the protein was still found in inclusion bodies. In addition, the soluble protein would not bind to the nickel-NTA resin. This suggested that the N terminus of the BCATm fusion protein was somewhat buried, making the histidine tag inaccessible to the resin. Upon complete denaturation in 8 M urea, BCATm bound to the resin; however, active enzyme could not be recovered either by gradual refolding of the protein while it remained on the resin or by dialysis versus urea-free buffer. In 4 M urea, the tertiary or quaternary structure of the protein was altered enough to permit binding of the N-terminal histidine tag to the resin. The far UV CD spectrum of BCATm (data not shown) showed no detectable change upon increasing urea concentrations from 0 through 4 M, thus indicating that the secondary structure of BCATm remained intact. In 4 M urea, the specific activity of the enzyme was reduced about 50% but could be restored after gradual removal of the denaturant. The use of 4 M urea also increased the yield of recombinant protein. Specific activity of purified BCATm after thrombin cleavage was 88 ± 6 units/mg of protein (n = 3). The N-terminal sequence of the recombinant protein carries the additional amino acids gshm (these additional residues are listed throughout in lowercase italic type) as verified by amino acid sequencing (see Fig. 1). SDS-PAGE of the purified recombinant BCATm protein is shown in Fig. 2A.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   SDS-PAGE of purified human BCATm and BCATc. 3-5 µg of protein were loaded onto the gels, and molecular mass standards are indicated. Panel A shows BCATm after cleavage of the histidine tag by thrombin (41.7 kDa). Panel B shows BCATc expressed using the pTrcHis vector (44.3 kDa), and panel C shows BCATc expressed using the pET-28a vector following removal of the histidine tag (43.4 kDa).

For BCATc, initial attempts with expression plasmids driven by the highly processive T7 RNA polymerase were problematic, because the protein was found primarily in inclusion bodies. With the lower level of expression found with the pTrcHis construct, the solubility of the recombinant protein was increased. Recently, we have expressed BCATc using the pET-28a vector/T7 expression system and removed the histidine tag. Although some protein was still found in inclusion bodies, the high yield in the pET vector/T7 system permitted purification of sufficient protein for kinetic and structural analysis. SDS-PAGE of the purified recombinant BCATc proteins is shown in Fig. 2, B and C. Unlike BCATm, recombinant BCATc readily bound to the nickel-NTA resin under native conditions, indicating that the N terminus of BCATc was exposed to the solvent, and urea addition (4 M) did not improve recovery. Thus, the behavior of the recombinant proteins on the nickel-NTA resin suggests that in the N-terminal portion of the proteins, the tertiary structure of BCATm and BCATc is different. Specific activity of BCATc, with or without the histidine tag, was 124 ± 9 units/mg of protein (n = 5). Recombinant BCATc expressed using the pTrcHis construct (phBCATc) contained an additional 14 amino acid residues (mggshhhhhhgmas) at the N terminus of the recombinant protein that were contributed by the vector sequence. The protein expressed using the pET-28a vector construct (phBCATc2) contained six additional amino acids after thrombin cleavage. Both nucleotide sequencing of the phBCATc2 construct and N-terminal amino acid sequencing of the recombinant protein showed that the N-terminal extension was gshmac (see Fig. 1). The N-terminal sequence of the recombinant protein with the histidine tag (phBCATc) was also confirmed by direct amino acid sequence analysis. Preliminary experiments showed that the physical and kinetic properties of the two recombinant enzymes were similar, and both enzymes were used in subsequent experiments.

Sedimentation Equilibrium-- Upon size exclusion chromatography, purified rat BCATm behaved anomalously and appeared to be a monomer, while rat BCATc was clearly a homodimer (9, 10). To determine unequivocally the subunit composition of the human isoenzymes, equilibrium sedimentation experiments were performed with the recombinant proteins. After the data were subjected to curve fitting analysis, BCATm and BCATc showed average molecular weights of 81,500 ± 2510 and 83,900 ± 4800, respectively. These values are approximately twice the calculated monomer molecular weights of the recombinant proteins after thrombin cleavage, 41,700 (BCATm) and 43,400 (BCATc), identifying both enzymes as dimers in solution.

Spectral Analysis of Recombinant Human BCAT Isoenzymes-- The absorption spectra of the recombinant enzymes at pH 7.5 are shown in Fig. 3. In addition to the peak at 280 nm, two peaks characteristic of bound cofactor are observed at 416 and 326 nm, indicating the pyridoxal and pyridoxamine forms, respectively. In the visible range, the spectra for each isoenzyme are essentially superimposable. The higher absorption of BCATc at 280 nm probably reflects the higher tyrosine and tryptophan content of this protein. Extinction coefficients at 280 nm were determined for each protein. Values were 67,600 M-1 cm-1 per BCATm monomer and 86,300 M-1 cm-1 and 80,000 M-1 cm-1 per BCATc monomer, without and with the histidine tag, respectively.


View larger version (19K):
[in this window]
[in a new window]
 
Fig. 3.   UV-visible spectra of human BCATc and BCATm in the PLP and PMP forms. The proteins were converted to the PLP and PMP forms as described under "Materials and Methods." Proteins (0.01 mM) were in 10 mM phosphate buffer, pH 7.5. Solid line, BCATc PLP form; dashed line, BCATc PMP form; dotted line, BCATm PLP form; dash-dot-dash line, BCATm PMP form.

Fig. 4 shows the far and near UV CD spectra of the proteins. The far UV CD spectra of both BCATc and BCATm in their PLP and PMP forms have similar features with minima at 219 and 210 nm and a maximum at 193 nm (see Fig. 4A). alpha -Helical structure is normally characterized by the presence of two minima at 222 and 208-210 nm and a maximum at 191-193 nm (31); therefore, alpha -helices are present in both of these proteins. beta -Sheets are also present because a minimum occurs at 219 nm, which is close to the minimum (216-218 nm) normally observed for beta -forms (31). The similarity of the far UV CD spectra of the two proteins indicates that their secondary structure content is similar. In addition, secondary structure estimates calculated using the far UV CD spectra of the PLP form of the enzymes suggested an alpha -helix content of 38% for BCATm and 35% for BCATc. Predicted beta -sheet was on the order of 20-24%. As shown in Fig. 4, no major change occurred in the global structure of the proteins upon conversion of the PLP form to the PMP form, and predicted alpha -helix content was similar for the PMP forms (33% for BCATm and 36% for BCATc). The crystal structure of the PLP form of the smaller E. coli BCAT (34 kDa) revealed a secondary structure content of 39% alpha -helix and 41% beta -sheet (21). The similarity of the predicted alpha -helix content in the human BCAT proteins and observed alpha -helix content in the bacterial enzyme structure is also consistent with the hypothesis that all of these forms of the enzymes have the same basic folded structure.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 4.   Circular dichroism spectra of BCATc and BCATm in the PLP and PMP forms. Spectra from the far UV range are shown in panel A, and spectra from the near UV range are shown in panel B. Conditions were as described under "Materials and Methods." Lines used are the same as in Fig. 3.

The near UV CD spectra of the PLP form of both BCATm and BCATc were dominated by a band at 421 nm (see Fig. 4B). This peak resulted from the presence of the pyridoxal group in an asymmetric environment. Despite the similarity of this peak, there was a major difference in the spectrum of BCATc compared with BCATm around 280 nm. While BCATc showed a peak at 285 nm with a positive ellipticity, BCATm showed a peak at 270 nm with a negative value. Upon conversion of the PLP form to the PMP form, the peak at 421 nm disappeared for both proteins. For BCATm, this was concomitant with the appearance of a weaker band at 326 nm as well as a major increase in the intensity of the band at 277 nm. When the PLP form of BCATc was converted to the PMP form, the positive ellipticity of the peak at 285 nm was changed to a negative value. Since the far UV CD spectra of the PLP form of BCATm and BCATc were very similar to their respective PMP forms (see Fig. 4A), the conversion of PLP to PMP did not seem to affect the global structure of the proteins. Consequently, the changes observed around 280 nm could be assigned to an altered asymmetric environment of the aromatic residues in the active site. Furthermore, based on the difference in intensity and sign of the ellipticity of peaks around 280 nm, the structure of the active site in BCATc appears different from BCATm.

DTNB Titration-- Like their rat counterparts (9), human BCATm, unlike human BCATc, must be stored in a reducing environment, and all four enzymes require the addition of DTT to the assay for maximal activity, whereas the bacterial protein from Salmonella typhimurium, which contains three cysteine residues, is not sensitive to sulfhydryl reagents (32). The requirement for the presence of a reducing agent indicates a unique property of the mammalian aminotransferases, i.e. a relationship between the state of reduction of the cysteines in the proteins and activity of the enzymes. Therefore, to evaluate whether modification of sulfhydryl groups within these proteins altered their catalytic capacity, DTNB titrations were performed on both human enzymes.

Based on the primary sequence, BCATm contains six cysteine residues/monomer (see Fig. 1). As shown in Table I, two -SH groups/monomer were titrated with native enzyme. Upon denaturation, 5.7 -SH groups were titrated, indicating that no disulfide bonds were present. However, upon storage of BCATm for a few days in the absence of DTT, the number of titratable -SH groups decreased to 3.7, suggesting that a disulfide bond was gradually being formed. This process was accompanied by a decrease in the specific activity of the enzyme. Fig. 5 shows an SDS-PAGE of BCATm stored in the absence of DTT. Lane A shows that a more compact structure gradually forms upon storage without a reducing agent. As shown in lane B, the addition of DTT prior to loading the sample on the gel led to the disappearance of the lower band; thus, this faster migrating band results from the formation of a disulfide bond. This is consistent with the observation that the number of titratable cysteines decreases over time in the absence of DTT.

                              
View this table:
[in this window]
[in a new window]
 
Table I
DTNB titration of BCATm and BCATc
Proteins (2 µM) were incubated with a 100-fold molar excess of DTNB in the absence (native) or presence (denatured) of 6 M guanidine hydrochloride. Titrations were performed at 25-27 °C in 50 mM Tris-HCl, pH 7.0. Results are the average of 3-6 different titrations. Total number of cysteine residues per enzyme is taken from the deduced amino acid sequence for each protein.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 5.   SDS-PAGE of human BCATc and BCATm under reducing and nonreducing conditions. Proteins were stored for 3-5 days in the absence of reducing reagent. 3-5 µg of protein/lane were loaded onto the gel, and 5 mM DTT was added to the indicated samples. STD, molecular mass markers; lane A, BCATm (41.7 kDa) without DTT; lane B, BCATm plus DTT; lane C, BCATc (44.3 kDa) without DTT; lane D, BCATc plus DTT.

The cytosolic isoenzyme contains 10 cysteines/monomer, yet only one -SH group was titrated in the native form of the histidine-tagged BCATc (see Table I). The phBCATc2 construct added an extra cysteine residue immediately preceding the N-terminal methionone (see Fig. 1). An additional -SH group was titrated in the native form after removal of the histidine tag, suggesting that this cysteine was accessible to DTNB. In the denatured form, 4.6 (histidine-tagged) and 6.6 (without histidine tag) -SH groups were seen, indicating that at least two disulfide bonds are present in BCATc. This conclusion is supported by the electrophoretic movement of the protein (see Fig. 5, lanes C and D). In the absence of DTT, BCATc migrated faster than when DTT was present. This increased mobility under nonreducing conditions suggests that the enzyme maintains a more compact structure due to the presence of disulfide bonds (33).

The activity of rat BCATm is known to be inhibited by sulfhydryl reagents (9), so the effect of DTNB on activity of the human enzymes was investigated. Spectrophotometric titration of BCATm with a 100-fold molar excess of DTNB occurred rapidly, and human BCATm activity was inhibited 90-100% after titration of both accessible -SH groups. By reducing the ratio of DTNB to enzyme to 5, the reaction could be slowed such that essentially one -SH group was titrated after 6 min. To determine the effect of this titration on BCATm activity, the protein was incubated with DTNB for 6 min in assay buffer without DTT. Then substrate was added, and activity was followed for 20 min. Without DTT, the enzyme does not have maximal activity, so a sample under identical assay conditions without DTNB was used as a control. As shown in Fig. 6, BCATm activity was decreased 40% after incubation with DTNB. Therefore, it appears that labeling of one -SH group by DTNB is not enough to fully inactivate BCATm. When substrate was added along with DTNB in the spectrophotometric assay, no -SH groups were titrated. Further, after incubation with DTNB in the presence of substrate, BCATm activity was unaltered (see Fig. 6), indicating that substrate protects against labeling and inhibition. Therefore, the modified -SH group may lie in or near the active site of BCATm, and studies are now in progress to verify its location. As shown in Fig. 6, titration of the single accessible -SH group in the histidine-tagged BCATc did not affect enzyme activity. Similar results were obtained with BCATc without the histidine tag (data not shown). This suggests that the modified residue is away from the active site. Since it is known that the catalytic mechanism of transamination does not require a cysteine residue, one could speculate that the loss of activity seen with BCATm is due to steric hindrance from the introduction of the bulky DTNB molecule in the active site. Another possibility is that this effect results from a conformational change in the enzyme. Possible candidate cysteines in BCATm are the two cysteine that are not conserved in the BCATc sequence (Cys108 and Cys168, see Fig. 1). Ultimately, however, understanding the effects of sulfhydryl reagents on catalytic function and protein stability (see below) will require isolation of the derivatized peptides and knowledge of the crystal structure of both proteins.


View larger version (65K):
[in this window]
[in a new window]
 
Fig. 6.   The effect of incubation with DTNB on the activity of BCATm and histidine-tagged BCATc. Enzymes were preincubated with a 5-fold molar excess of DTNB for either 6 min (BCATm) or 12 min (BCATc). Substrate was added, and product formation was followed for 20 min. Values are expressed as a percentage of the control, which contained no DTNB, after 20 min. Product formation was also measured after preincubation with substrate and DTNB added simultaneously. Open bar, control sample; filled bar, DTNB only; hatched bar, substrate and DTNB. In a separate spectrophotometric titration assay, it was determined that after 6-min (BCATm) and 12-min (BCATc) incubation with a 5-fold excess of DTNB, one -SH group was titrated in either enzyme.

The Effect of Ni2+ Cations on the Activity of BCATc and BCATm-- Affinity chromatography using nickel-NTA resin is based on the interaction of the histidine tag in the protein with nickel cations chelated to the resin. After elution from this column, human BCATm had low specific activity, which did not increase even after the second purification step of hydrophobic interaction chromatography. However, when EDTA was added to the assay, the specific activity increased to about 75 µmol/min/mg of protein or higher. Further, the addition of Ni2+ cations to the assay led to 67% inactivation of the purified enzyme, while subsequent addition of EDTA restored activity completely. On the other hand, when DTT or beta -mercaptoethanol was omitted from the assay, added Ni2+ had no inhibitory effect on BCATm activity. One possible explanation for these results is that one or more disulfide bonds are reduced by either DTT or beta -mercaptoethanol, allowing interaction of Ni2+ with cysteine residues within the active site. This seems unlikely, because in freshly purified BCATm, titration with DTNB suggests that no disulfide bonds are present. Alternatively, one can hypothesize that empty coordinates of Ni2+ cations bound in or near the active site of BCATm interact with the thiol groups of DTT or beta -mercaptoethanol, leading to either steric hindrance or a conformational change.

Chemical Denaturation of BCATc and BCATm-- Since BCATc contains two or three disulfide bonds, one expects to see a higher stability for this protein compared with BCATm; therefore, chemical denaturation experiments were performed to compare the two proteins. Fig. 7 shows the urea denaturation of BCATc and BCATm as monitored by CD spectroscopy. Human BCATm remains partially folded up to a urea concentration of 8 M, indicating high structural stability. On the other hand, the denaturation curve of BCATc appeared as a relatively broad transition with a midpoint of 4.1 M urea. Surprisingly, this suggests that the structural stability of BCATc is lower than BCATm. It is generally accepted that disulfide bonds can make a substantial contribution to the stability of proteins (33); however, for BCATc, it seems that this is not the case. Moreover, the broadness of the transition indicates that unfolding of BCATc is less cooperative than BCATm. Since chemical denaturation using urea or guanidine hydrochloride is irreversible, the free energy of denaturation could not be calculated. Nonetheless, the data suggest that there are differences in the stability of the secondary structure of the two proteins.


View larger version (16K):
[in this window]
[in a new window]
 
Fig. 7.   The effect of urea denaturation on the circular dichroism spectra of BCATc and BCATm. The PLP form of each enzyme at 0.1 mg/ml was incubated overnight at room temperature with various concentrations of urea in 10 mM potassium phosphate buffer, pH 8.0. Open circles represent BCATm, and filled circles represent BCATc.

Kinetic Parameters-- The steady state kinetics of BCATm and BCATc were examined, and the calculated Michaelis-Menten parameters are summarized in Table II. Transamination of branched-chain amino acids with alpha -ketoglutarate exhibited kinetics similar to what has been reported for the rat enzymes. Values calculated for the Km for leucine and isoleucine were around 1.0 mM or less with a significantly higher Km observed with valine. Differences between the two isoenzymes were also found. First, the Km values for leucine and valine were lower for BCATc than for BCATm. Observed kcat values suggested that the mitochondrial enzyme turns over faster using leucine than isoleucine and valine, but kcat/Km values were higher for isoleucine with both enzymes, suggesting preference for this branched-chain amino acid. For reamination of the branched-chain alpha -keto acids, generally Km values for the alpha -ketoacids were about 2-fold lower for BCATc than for BCATm. With both isoenzymes, the Km for KIC was similar with either fixed substrate (glutamate or isoleucine), whereas the Km for KIV paired with glutamate was 2.5-fold higher than when the fixed substrate was isoleucine.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Kinetic constants for the reactions of human branched-chain aminotransferase isoenzymes
Branched-chain aminotransferase activity was measured as described under "Materials and Methods." The fixed substrates were 10 × Km. Glutamate was fixed at 100 mM. Km and Vmax values (used to calculate kcat) were obtained from hyperbolic plots fit to the Michaelis-Menten equation. Means and S.E. values are from 3-5 separate determinations.

The possibility that the observed differences in kinetic parameters with KIV/Glu and KIV/Ile were a result of differences in ionic strength was investigated by adding KCl to the alpha -ketoacid/Ile assay buffer (see Table II). The addition of 150 mM KCl raised the apparent Km values for KIV and KIC 2-fold or more. Smaller effects were observed on kcat, resulting in a decrease in kcat/Km for both isoenzymes. The effect of added KCl on branched-chain amino acid deamination was also examined in a single set of experiments. Increases of 40-50% in the Km values for Leu and Ile were found with BCATm. Both Km and kcat were increased with BCATc (data not shown). While the molecular basis for the effects of K+ and/or Cl- on the kinetic parameters of the BCAT isoenzymes is not yet understood, there is precedence for both cation and anion effects on PLP-dependent enzymes (35-39). The structural basis for the cation stimulation of tryptophan synthase (35), dialkylglycine decarboxylase (40), tryptophanase (41), and tyrosine phenol-lyase (42) have been investigated using x-ray crystallography, and cation binding sites have been defined. In both tryptophanase (43, 44) and tyrosine phenol-lyase (45) from E. coli, cations like K+ were shown to induce and stabilize active conformations of these enzymes. With aspartate aminotransferase, at alkaline pH, it was shown that chloride anions (38) as well as dicarboxylic acids (46) can act as competitive inhibitors, possibly by ion pairing with positively charged residues in the active site that serve to bind the alpha -carboxylate group of the substrate.

In the absence or presence of KCl, kcat and kcat/Km values for the deamination of the branched-chain amino acids were higher for BCATc than BCATm, suggesting that BCATc turns over 2-5 times faster than BCATm. For reamination, generally kcat values between the two enzymes are similar; however, the markedly lower Km values for alpha -keto acids found with BCATc result in calculated kcat/Km values that are approximately 2-fold higher for KIC and 3-4-fold higher for KIV than found with BCATm. An equilibrium constant of 1.4 ± 0.1 was also determined with BCATm, and this value agrees quite well with the value of 1.7 originally reported by Taylor and Jenkins (3).

Substrate Specificity-- The amino acid preference of BCATc and BCATm was determined by examining the relative rate of transamination of [1-14C]KIC with the branched-chain amino acids, branched-chain amino acid analogs, and other amino acids. Rates relative to leucine are presented in Table III. As expected, branched-chain amino acids were clearly the preferred substrates. Glutamate was a better substrate for BCATc than BCATm, 82% of control versus 38%, respectively. This difference could be attributed to a lower Km for glutamate for BCATc (13 mM) versus BCATm (24 mM). Human BCATc appeared to accept the five-carbon straight chain analog, norvaline, twice as readily as BCATm. Depending on the isoenzyme, L-alloisoleucine was transaminated at about 50-80% of the rate of the natural substrate, L-threoisoleucine. D-Isoleucine, methionine, the aromatic amino acids, glutamine, alanine, and aspartate were not accepted by either enzyme.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Substrate specificity of BCATc and BCATm for amino acids
Branched-chain aminotransferase activity was determined as described under "Materials and Methods" using [1-14C]KIC and 10 mM amino acid. The [1-14C]KIC concentration was set at 10 × Km, 0.6 and 1.7 mM, for BCATc and BCATm, respectively. Aminotransferase activity is expressed relative to 10 mM leucine and was 131 µmol of leucine formed/mg of protein/min for both isoenzymes. Means and S.D. values from three separate determinations are presented.

The range of alpha -keto acid substrates is shown in Table IV. Rates are shown relative to KIC and [1-14C]leucine. The pattern of alpha -keto acids accepted by the human isoenzymes is virtually identical. As expected, the hydroxy acids of leucine (alpha -hydroxyisocaproate) and valine (alpha -hydroxyisovalerate) were not substrates (see Table IV). The straight chain alpha -keto acids were good substrates, with the five-carbon alpha -ketovalerate preferred over the six-carbon alpha -ketocaproate. With five carbons, alpha -ketovalerate has the same chain length as isoleucine and leucine but without branching. alpha -Ketobutyrate was transaminated poorly compared with KIV, showing that, when the carbon length was 4, branching increased affinity for the enzyme. Both alpha -ketocaproate and alpha -keto-gamma -methiobutyrate have a carbon length of 6, but alpha -keto-gamma -methiobutyrate has a sulfur atom substituted at the fifth carbon position. alpha -Ketocaproate was favored over the alpha -keto acid of methionine, suggesting that the introduction of the bulky sulfur atom decreases the affinity of the enzyme. Pyruvate and phenylpyruvate were not accepted by either human isoenzyme. This pattern of amino and alpha -keto acid preferences is very similar to what has been reported for the rat BCAT isoenzymes (9). Thus, although differences in apparent substrate affinity and rates of transamination between BCATm and BCATc suggest localized variations in active site architecture, overall structure appears conserved within the mammalian BCAT.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
Substrate specificity of BCATc and BCATm for selected alpha -keto acids
Branched-chain aminotransferase activity was determined as described under "Materials and Methods" using 10 mM [1-14C]leucine and saturating alpha -keto acid at 0.6 and 1.7 mM for BCATc and BCATm, respectively. Radiolabeled CO2 was trapped as described in Ref. 7. Aminotransferase activity is expressed relative to the rate with KIC and was 163 and 130 µmol of KIC formed/mg of protein/min for BCATc and BCATm, respectively. Means and S.D. values from three separate determinations are presented.

    CONCLUSIONS
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
Conclusions
References

This paper presents the first overexpression and characterization of the human branched-chain aminotransferase isoenzymes. Our data show that the human BCAT share the basic characteristics of other known BCAT with respect to substrate specificity (1). Physical comparison of the recombinant proteins has also revealed subtle kinetic and physical differences in the two proteins with regard to stability, tertiary structure of the N-terminal regions of the proteins, and structure of the active sites. Although the structure of the E. coli protein has provided insight into the structure of the human BCAT, neither the E. coli nor the D-alanine aminotransferase structure appears to have sufficiently high sequence homology for use as a model in molecular replacement.2 Thus, understanding the molecular basis for the differences between the BCATc and BCATm proteins and their bacterial counterparts will require knowledge of the crystal structure of the mammalian BCAT. These experiments are currently in progress.

    FOOTNOTES

* This work was supported by Grant DK34738 (to S. M. H.) from the National Institutes of Health, United States Public Health Service. The Analytical Ultracentrifugation Facility at Wake Forest University was established in part through Institutional Development Grant 9510-IDG-1012 from the North Carolina Biotechnology Center.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed: Biochemistry Dept., Wake Forest University School of Medicine, Medical Center Blvd., Winston Salem, NC 27157. Tel.: 336-716-6055; Fax: 336-716-7671; E-mail: shutson{at}bgsm.edu.

1 The abbreviations used are: BCAT, branched-chain aminotransferase(s); BCATm, mitochondrial branched-chain aminotransferase; BCATc, cytosolic branched-chain aminotransferase; PLP, pyridoxal phosphate; PMP, pyridoxamine phosphate; DTNB, 5,5'-dithiobis(2-nitrobenzoic acid); KIC, alpha -ketoisocaproate; KIV, alpha -ketoisovalerate; DTT, dithiothreitol; NTA, nitrolotriacetic acid; PAGE, polyacrylamide gel electrophoresis.

2 Dr. Greg Farber, personal communication.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results & Discussion
Conclusions
References

  1. Ichihara, A. (1985) in Transaminases (Christen, P., and Metzler, D. E., eds), pp. 430-439, John Wiley & Sons, Inc., New York
  2. Ichihara, A., and Koyama, E. (1966) J. Biochem. (Tokyo) 59, 160-169[Medline] [Order article via Infotrieve]
  3. Taylor, R. T., and Jenkins, W. T. (1966) J. Biol. Chem. 241, 4396-4405[Abstract/Free Full Text]
  4. Inoue, K., Kuramitsu, S., Aki, K., Watanabe, Y., Takagi, T., Nishigai, M., Ikai, A., and Kagamiyama, H. (1988) J. Biochem. (Tokyo) 104, 777-784[Abstract]
  5. Feild, M. J., Nguyen, D. C., and Armstrong, F. B. (1989) Biochemistry 28, 5306-5310[Medline] [Order article via Infotrieve]
  6. Kanda, M., Hori, K., Kurotsu, T., Ohgishi, K., Hanawa, T., and Saito, Y. (1995) J. Nutr. Sci. Vitaminol. (Tokyo) 41, 51-60[Medline] [Order article via Infotrieve]
  7. Hutson, S. M., Fenstermacher, D., and Mahar, C. (1988) J. Biol. Chem. 263, 3618-3625[Abstract/Free Full Text]
  8. Hutson, S. M., Wallin, R., and Hall, T. R. (1992) J. Biol. Chem. 267, 15681-15686[Abstract/Free Full Text]
  9. Hall, T. R., Wallin, R., Reinhart, G. D., Hutson, S. M. (1993) J. Biol. Chem. 268, 3092-3098[Abstract/Free Full Text]
  10. Wallin, R., Hall, T. R., and Hutson, S. M. (1990) J. Biol. Chem. 265, 6019-6024[Abstract/Free Full Text]
  11. Hutson, S. M., Bledsoe, R. K., Hall, T. R., Dawson, P. A. (1995) J. Biol. Chem. 270, 30344-30352[Abstract/Free Full Text]
  12. Bledsoe, R. K., Dawson, P. A., and Hutson, S. M. (1997) Biochim. Biophys. Acta 1339, 9-13[Medline] [Order article via Infotrieve]
  13. Schuldiner, O., Eden, A., Ben-Yosef, T., Yanuka, O., Simchen, G., and Benvenisty, N. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7143-7148[Abstract/Free Full Text]
  14. Eden, A., Simchen, G., and Benvenisty, N. (1996) J. Biol. Chem. 271, 20242-20245[Abstract/Free Full Text]
  15. Welty, D. F., Schielke, G. P., and Rothstein, J. D. (1995) Ann. Pharmacother. 29, 1164-1167[Abstract]
  16. Kispal, G., Steiner, H., Court, D. A., Rolinski, B., Lill, R. (1996) J. Biol. Chem. 271, 24458-24464[Abstract/Free Full Text]
  17. Tanizawa, K., Asano, S., Masu, Y., Kuramitsu, S., Kagamiyama, H., Tanaka, H., and Soda, K. (1989) J. Biol. Chem. 264, 2450-2454[Abstract/Free Full Text]
  18. Grishin, N. V., Phillips, M. A., and Goldsmith, E. J. (1995) Protein Sci. 4, 1291-1304[Abstract/Free Full Text]
  19. Yoshimura, T., Nishimura, K., Ito, J., Esaki, N., Kagamiyama, H., Manning, J. M., Soda, K. (1993) J. Am. Chem. Soc. 115, 3897-3900
  20. Sugio, S., Petsko, G. A., Manning, J. M., Soda, K., Ringe, D. (1995) Biochemistry 34, 9661-9669[Medline] [Order article via Infotrieve]
  21. Okada, K., Hirotsu, K., Sato, M., Hayashi, H., and Kagamiyama, H. (1997) J. Biochem. (Tokyo) 121, 637-641[Abstract]
  22. Lee-Ping, F. C., Hermodson, M. A., and Kohlhaw, G. B. (1979) J. Bacteriol. 139, 339-345[Medline] [Order article via Infotrieve]
  23. Perczel, A., Hollosi, M., Tusnady, G., and Fasman, G. D. (1991) Protein Eng. 4, 669-679[Abstract]
  24. Perczel, A., Park, K., and Fasman, G. D. (1992) Anal. Biochem. 203, 83-93[Medline] [Order article via Infotrieve]
  25. Riddles, P. W., Blakeley, R. L., and Zerner, B. (1979) Anal. Biochem. 94, 75-81[Medline] [Order article via Infotrieve]
  26. Williamson, J. R., and Corkey, B. E. (1969) Methods Enzymol. 13, 434-513
  27. Cleland, W. W. (1963) Biochim. Biophys. Acta 67, 104-137[CrossRef]
  28. Cleland, W. W. (1967) Adv. Enzymol Relat. Areas Mol. Biol. 29, 1-32[Medline] [Order article via Infotrieve]
  29. Laue, T. M., Shah, B. D., Ridgeway, T. M., Pelletier, S. L. (1992) in Analytical Ultracentrifugation in Biochemistry and Polymer Science (Harding, S. E., Rowe, A. J., and Harton, J. C., eds), pp. 97-103, Redwood Press, Ltd., Melksham, Wiltshire, United Kingdom
  30. Laemmli, U. K. (1970) Nature 680-685
  31. Yang, J. T., Wu, C. S. C., and Martinez, H. M. (1986) Methods Enzymol. 130, 208-269[Medline] [Order article via Infotrieve]
  32. Lipscomb, E. L., Horton, H. R., and Armstrong, F. B. (1974) Biochemistry 13, 2070-2077[Medline] [Order article via Infotrieve]
  33. Matsumura, M., and Matthews, B. W. (1991) Methods Enzymol. 202, 2336-2356
  34. Devereux, J., Haeberli, P., and Smithies, O. (1984) Nucleic Acids Res. 12, 387-395[Abstract]
  35. Ben-Kasus, T., Markel, A., Gdalevsky, G. Y., Torchinsky, Y. M., Phillips, R. S., Parola, A. H. (1996) Biochim. Biophys. Acta 1294, 147-152[Medline] [Order article via Infotrieve]
  36. Tokushige, M., Tsujimoto, N., Oda, T., Honda, T., Yumoto, N., Ito, S., Yamamoto, M., Kim, E. H., Hiragi, Y. (1989) Biochimie 71, 711-720[Medline] [Order article via Infotrieve]
  37. Rhee, S., Parris, K. D., Ahmed, A., Miles, E. W., Davies, D. R. (1996) Biochemistry 35, 4211-4221[CrossRef][Medline] [Order article via Infotrieve]
  38. Cheng, S., Michuda-Kozak, C., and Martinez-Carrion, M. (1971) J. Biol. Chem. 246, 3623-3630[Abstract/Free Full Text]
  39. Harruff, R. C., and Jenkins, W. T. (1978) Arch. Biochem. Biophys. 188, 37-46[Medline] [Order article via Infotrieve]
  40. Toney, M. D., Hohenester, E., Keller, J. W., Jansonius, J. N. (1995) J. Mol. Biol. 245, 151-179[CrossRef][Medline] [Order article via Infotrieve]
  41. Isupov, M., Dementieva, I., Zakomirdina, L., Wilson, K. S., Dauter, Z., Antson, A. A., Dodson, G. G., Harutyunyan, E. G. (1994) in Biochemistry of Vitamin B6 and PQQ (Marino, G., Sannia, G., and Bossa, F., eds), pp. 183-185, Birkhauser, Basel, Switzerland
  42. Antson, A. A., Dodson, G. G., Wilson, K. S., Pletney, S. V., Dauter, Z., Harutyunyan, E. G., Demidkina, T. V. (1994) in Biochemistry of Vitamin B6 and PQQ (Marino, G., Sannia, G., and Bossa, F., eds), pp. 187-191, Birkhauser Verlag, Basel, Switzerland
  43. Honda, T., and Tokushige, M. (1986) J. Biochem. (Tokyo) 100, 679-685[Abstract]
  44. Toraya, T., Nihira, T., and Fukui, S. (1976) Eur. J. Biochem. 69, 411-419
  45. Demidkina, T. V., and Myagkikh, I. V. (1989) Biochimie 71, 565-571[Medline] [Order article via Infotrieve]
  46. Michuda, C. M., and Martinez-Carrion, M. (1970) J. Biol. Chem. 245, 262-269[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.